GL1X · GenesisL1 explorer

MolNFT v1 · #86669 · protein

Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)

4BDK: “Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase 2 (CHK2)”. X-ray diffraction, 2 ligands (RQQ, NO3), 3 pockets (best druggability 0.57). MolNFT v1 #86669 on GenesisL1: 3D structure, binding…

PDB
4BDK
Type
protein
Length
286 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Checkpoint kinase 2
EC
2.7.11.1
UniProt
O96017
Ligands
RQQ, NO3
Pockets
3 · best druggability 0.57

Structure

x-ray diffraction · 1 distinct chain · 43% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACheckpoint kinase 2 (EC 2.7.11.1)protein28643% helix, 16% strandO96017

Ligands and binding sites

  • RQQ · N-[(4-methoxyphenyl)methyl]quinoxaline-6-carboxamide · ligand · chains A
  • NO3 · Nitrate ion · ion · chains A
  • EDO · 1,2-ethanediol · additive · 3 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12140.570.7929RQQ, EDO
2730.300.7319empty
3550.260.7312empty

Compared structures

  • 4BDK · Fragment-based screening identifies a new area for inhibitor binding to checkpoint kinase… · the same entry in another collection · chain A against A, TM-score 1.00
  • O96017 · AlphaFold monomer V2.0 prediction for SERINE/THREONINE-protein kinase CHK2 (O96017) · a predicted model of the same protein · chain A against A, TM-score 0.85

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.